Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
Larry J AndersonNadine G RouphaelAlicia T WidgeLisa A JacksonPaul C RobertsMamodikoe MakheneJames D ChappellMark R DenisonLaura J StevensAndrea J PruijssersAdrian B McDermottBritta FlachBob C LinNicole A Doria-RoseSijy O'DellStephen D SchmidtKizzmekia S CorbettPhillip A SwansonMarcelino PadillaKathy M NeuzilHamilton BennettBrett LeavMat MakowskiJim AlbertKaitlyn CrossVenkata Viswanadh EdaraKatharine FloydMehul S SutharDavid R MartinezRalph BaricWendy BuchananCatherine J LukeVarun K PhadkeChristina A RostadJulie E LedgerwoodBarney S GrahamJohn H Beigelnull nullPublished in: The New England journal of medicine (2020)
In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100-μg dose in a phase 3 vaccine trial. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 Study ClinicalTrials.gov number, NCT04283461.).